Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 54 systematic review(s)/meta-analysis(es). ^[1-54]
• Conbercept (IVC) demonstrated non-inferior efficacy to ranibizumab (RBZ) in improving visual acuity, achieving significant gains over placebo and other comparators in conditions like diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), with comparable outcomes to RBZ at 3 and 6-12 months.
• Aflibercept (IVT-AFL) matched the visual acuity improvements of RBZ across various indications, including DME and nAMD, with greater benefits in patients with poorer baseline vision and required fewer injections in treat-and-extend (T&E) regimens.
• Bevacizumab showed similar visual acuity improvement to RBZ, though it was associated with less central macular thickness (CMT) reduction after 1 year, indicating comparable effectiveness with slight differences in retinal thickness outcomes.
• Newer anti-VEGF agents, such as faricimab and brolucizumab, provided comparable or superior outcomes in CMT reduction and visual acuity improvement, while significantly reducing injection frequency compared to RBZ, offering a potential advantage in treatment burden management.
• Conbercept (IVC) did not show a definitive increase in ocular or systemic adverse events compared to ranibizumab (RBZ), maintaining a similar safety profile across various conditions.
• No significant differences in serious ocular or systemic adverse events were found between ranibizumab and aflibercept (IVT-AFL), although brolucizumab exhibited a higher risk of serious ocular adverse events relative to RBZ.
• Bevacizumab showed no significant difference in serious ocular or systemic adverse events compared to RBZ, supporting its similar safety profile in clinical use.
• Faricimab demonstrated a reduction in serious ocular adverse events compared to brolucizumab, indicating a potential safety advantage among newer anti-VEGF agents.
• In diabetic macular edema (DME) patients, conbercept (IVC) and aflibercept (IVT-AFL) showed significant efficacy in visual acuity improvement and central macular thickness (CMT) reduction compared to ranibizumab (RBZ), with aflibercept providing additional benefits in patients with poorer baseline vision. Faricimab offered superior retinal drying effects in DME compared to RBZ, though brolucizumab posed a higher risk of ocular adverse events in this population.
• For neovascular age-related macular degeneration (nAMD), conbercept and aflibercept demonstrated similar efficacy to RBZ in visual acuity and CMT reduction, with aflibercept requiring fewer injections. Brolucizumab and faricimab showed enhanced retinal thickness reduction, with faricimab displaying a favorable safety profile compared to brolucizumab.